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Scaling-up co-trimoxazole prophylaxis in HIV-exposed and 
HIV-infected children in high HIV-prevalence countries
Rony Zachariah, Anthony D Harries, Chewe Luo, Gretchen Bachman, Stephen M Graham
Co-trimoxazole (trimethoprim-sulfamethoxazole) is a widely available antibiotic that substantially reduces HIV-related 
morbidity and mortality in both adults and children. Prophylaxis with co-trimoxazole is a recommended intervention 
of proven beneﬁ  t that could serve not only as an initial step towards improving paediatric care in young children with 
limited access to antiretroviral treatment, but also as an important complement to antiretroviral therapy in resource-
limited settings. Despite co-trimoxazole’s known clinical beneﬁ  ts, the potential operational beneﬁ  ts, and favourable 
recommendations by WHO, UNAIDS, and UNICEF, its routine use in developing countries—particularly sub-
Saharan Africa—has remained limited. Out of an estimated 4 million children in need of co-trimoxazole prophylaxis 
(HIV-exposed and HIV-infected), only 4% are currently receiving this intervention. We discuss some of the major 
barriers preventing the scale-up of co-trimoxazole prophylaxis for children in countries with a high prevalence of HIV 
and propose speciﬁ  c actions required to tackle these challenges.
Introduction
At the end of 2006, there were an estimated 2·3 million 
children worldwide living with HIV, an estimated 530 000 
new HIV infections occurred, and 380 000 children died 
from AIDS.
1 An estimated 780 000 children are in urgent 
need of antiretroviral therapy (ART)
 and this number is 
constantly increasing.
2,3 Most of these children live in 
sub-Saharan Africa, where only 10% currently access 
treatment.
2–6 Despite the growing intensity of current 
eﬀ  orts to oﬀ  er ART to children living in resource-limited 
settings, substantial obstacles remain, which include: 
limited training and experience of providers in treating 
children; the lack of practicable, easy-to-use paediatric 
antiretroviral form  ulations; no ﬁ  xed-dose combinations 
making treatment more diﬃ   cult  to  administer  and 
adhere to;
7 the high cost of paediatric antiretroviral drugs 
that may be up to ten times more expensive than the 
corresponding adult formulations;
8 and the lack of 
aﬀ  ordable and simple technologies for conﬁ  rming HIV 
infection in children under 18 months of age. It is 
therefore likely to be some time before infrastructure 
and resources permit many more children to access life-
saving ART.  
In the meantime, co-trimoxazole (trimethoprim-
sulfamethoxazole) is a recommended intervention of 
proven beneﬁ   t that could improve paediatric care in 
young children and act as an important complement to 
ART in resource-limited settings. 
Beneﬁ  ts of co-trimoxazole prophylaxis in HIV-
infected infants and children
Co-trimoxazole is a widely available, easy to administer, 
safe, and low-cost antibiotic that still appears as a ﬁ  rst-
line drug on formularies of developing countries. It has a 
broad-spectrum prophylactic action against common 
bacterial pathogens, Pneumocystis jirovecii (formerly 
Pneumocystis carinii) , and protozoa such as Plasmodium 
spp and Isospora belli. Randomised controlled trials 
(RCTs)
9,10 and studies with historical controls
11–16 in HIV-
infected African adults consistently show signiﬁ  cant 
beneﬁ  ts in survival for those receiving co-trimoxazole 
prophylaxis. These improvements in survival have been 
accompanied by substantial reductions of severe disease 
events and the number of hospital admissions linked to 
invasive bacterial disease, pneumonia, malaria, and 
diarrhoea, although disease-speciﬁ  c beneﬁ  t has varied 
between studies.
9.10,14,16 The only RCT done in children was 
in HIV-infected Zambian children aged 1–14 years, which 
found a highly signiﬁ  cant beneﬁ  t of co-trimoxazole in 
improving survival and reducing hospitalisations and 
pneumonia (hazard ratio 0·57 [95% CI 0·43–0·77], 
p=0·0002).
17 Many of the studies showing beneﬁ  t have 
been in communities where in-vitro co-trimoxazole 
resistance to common bacterial isolates is already 
high.
14,16–18
It is well recognised that P jirovecii is a common cause 
of pneumonia and death in HIV-infected infants.
19–22 The 
introduction of routine co-trimoxazole prophylaxis for 
infants at risk of HIV infection in several countries has 
been very eﬀ  ective in preventing P jirovecii pneumonia, 
which could in itself prevent a third to a half of all HIV-
related deaths in African infants.
23 
In addition to the clinical beneﬁ  ts of co-trimoxazole, 
there are several potential operational advantages. First, 
mothers are more likely to bring children to health-care 
centres for HIV testing and follow-up care if they know 
that an eﬀ  ective treatment is immediately available. This 
could also provide an opportunity to address HIV-related 
prevention and care issues for the mother and other 
family members. Second, co-trimoxazole prophylaxis 
provides an opportunity for systematic care of children at 
health facilities at lower levels of the health system and 
the observed stabilising eﬀ  ect on immune function and 
viral replication has the biological potential to delay the 
need for ART until it is available.
14  Third, co-trimoxazole 
could serve as a backbone for establishing and 
strengthening a chronic care infrastructure upon which 
interventions including ART could be built, since 
systematic delivery of co-trimoxazole requires a health-
care delivery system that will not only identify HIV-
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infected children but also ensure that they remain in the 
system. Fourth, co-trimoxazole prophylaxis provides an 
opportunity to model drug adherence approaches before 
starting ART.
24,25 Finally, co-trimoxazole prophylaxis is cost-
eﬀ   ective and could have important beneﬁ   ts for other 
family members.
26,27 
Co-trimoxazole has known clinical beneﬁ  ts, potential 
operational beneﬁ  ts, and is also recommended by WHO, 
UNAIDS, and UNICEF
23,28 for all HIV-exposed and HIV-
infected children until reliable conﬁ  rmation of HIV status 
has been made. However, the drug’s routine use in 
resource-limited settings—particularly sub-Saharan 
Africa—has remained limited. Out of an estimated 
4 million children who are in need of co-trimoxazole 
prophylaxis (HIV-exposed and HIV-infected), only 4% are 
currently receiving this intervention.
29 We discuss some of 
the major barriers preventing the scale-up of co-
trimoxazole prophylaxis for children in countries with a 
high prevalence of HIV and suggest speciﬁ  c actions to 
tackle them. Although these actions are proposed for high-
prevalence, resource-limited settings, they may be more 
widely relevant.
Barriers preventing scale-up of co-trimoxazole 
prophylaxis in infants and children
Hypothetical objections against widespread use of 
co-trimoxazole in high HIV-prevalence countries
Scaling-up co-trimoxazole as part of the minimum 
package of care in Africa was initially hampered by a 
number of legitimate concerns. The provisional WHO/
UNAIDS recommendations for Africa released in 2000
30 
were made on the basis of two studies,
9,10 both from 
Abidjan, Côte d’Ivoire, where at the time prevalence of 
bacterial resistance to co-trimoxazole was low. Clinicians 
and policymakers in Africa therefore doubted the eﬃ   cacy 
of co-trimoxazole in countries where co-trimoxazole 
resistance was known to be high, and so did not accept or 
apply the provisional recommendations. Since then, 
several studies have shown that co-trimoxazole 
prophylaxis improves survival and reduces serious 
disease events even in areas of Africa where in-vitro co-
trimoxazole resistance is common.
12–17 Furthermore, 
although resistance levels increase with time, as they 
have in Abidjan, this has not prevented the drug from 
being useful.
18 Co-trimoxazole’s eﬃ   cacy  against 
pneumocystis, isospora, and malaria might explain its 
favourable eﬀ  ects on morbidity and survival in endemic 
areas. 
Other major concerns of co-trimoxazole prophylaxis 
were that widespread use of the drug would accelerate 
the spread of multidrug resistance among common 
bacterial pathogens and increase resistance of Plasmodium 
falciparum  to sulfadoxine-pyrimethamine and other 
antifolate antimalarial drugs. From a broader public-
health perspective, this could mean reducing useful life 
of cheap and available ﬁ   rst-line therapies; from the 
individual clinical management perspective there are 
concerns that, for example, a patient with malaria would 
be more likely to fail treatment with sulfadoxine-
pyrimethamine if already taking co-trimoxazole 
prophylaxis. However, an RCT in children aged 5–15 years 
in Mali showed that co-trimoxazole prophylaxis does not 
appear to select for sulfadoxine-pyrimethamine-resistant 
P falciparum.
31 Furthermore, since sulfadoxine-
pyrimethamine is being phased out and replaced by 
more eﬀ  ective artemisinin-based combination therapies 
in most countries, concerns about antimicrobial 
resistance to sulfadoxine-pyrimethamine might become 
less relevant. 
By contrast, uncertainty remains about the possible 
impact of co-trimoxazole prophylaxis on the prevalence 
of antibiotic-resistant bacteria, with studies so far 
showing conﬂ  icting results for enteric isolates.
29,32 Since 
most of these studies were not speciﬁ  cally designed with 
the primary intention of studying drug resistance as a 
function of prophylaxis, the evidence base is not powerful 
enough to dismiss the risk of resistance developing, and 
speciﬁ  c ongoing surveillance is therefore justiﬁ  ed. The 
potential problem is not only for increased resistance to 
co-trimoxazole, which is already high in many settings, 
but also for worsening resistance to other antibiotics.
33 
However, co-trimoxazole prophylaxis may protect against 
development of resistance if it reduces the number of 
hospital admissions and the frequency of use of other 
antibiotics. 
Actions required
There is a need for consultative forums within countries 
that bring together key stakeholders at a national level, to 
disseminate information on current evidence, bridge 
gaps in knowledge, allay fears on use of co-trimoxazole at 
country level, and present the rationale for current 
recommendations.
29 The forums should also serve to 
boost leadership and to prepare the next steps for 
implementing a phased national co-trimoxazole scale-up 
plan that is integrated into child survival programmes. 
Focus should be placed on the following: a national 
coordination mechanism that is inclusive of all major 
actors; a district and facility-based scale-up plan that 
includes a clear deﬁ  nition of needs, targets, and required 
budgets; a national drug procurement and distribution 
system that includes drugs and commodities for 
paediatric care including co-trimoxazole; and a system of 
monitoring the number of adults and children accessing 
co-trimoxazole, which will be needed for forecasting drug 
orders. 
There is undoubtedly international importance in 
setting up surveillance monitoring programmes to 
follow microbial resistance emergence (eg, in enteric 
bacteria,  Plasmodium  spp, and pneumocystis) and to 
assess the ongoing eﬃ   cacy of widespread co-trimoxazole 
prophylaxis programmes. Research is also needed to 
evaluate the eﬃ   cacy of other antimicrobial agents for 
reducing morbidity and mortality of HIV-related 688   http://infection.thelancet.com   Vol 7   October 2007
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infections in high HIV-prevalence countries (with and 
without malaria). As microbial resistance increases, we 
will need to know whether other eﬀ  ective prophylactic 
regimens can be implemented and how this might be 
done on a large scale. Future scenario modelling and 
health economic assessments will be needed to gather 
this information.  
Inadequate policy guidance on co-trimoxazole 
prophylaxis
The provision of HIV/AIDS care in the low-resource 
setting has mainly focused on antiretroviral drugs for 
treatment of HIV and for prevention of mother-to-child 
transmission (PMTCT) of HIV. Little or no consideration 
has been given to co-trimoxazole prophylaxis. ART 
provision has also focused mainly on adults, and since 
policy guidance on co-trimoxazole is usually integrated 
within such guidelines, there is a resulting lack of 
guidance on co-trimoxazole prophylaxis for infants and 
children at the national level. Since 2006, WHO has 
begun to produce guidelines for use of co-trimoxazole 
and ART in infants and children.
Actions required
National policy guidelines on co-trimoxazole prophylaxis 
are required that explicitly separate adults and children. 
Panel 1 and panel 2 specify criteria for when to initiate 
and when to discontinue co-trimoxazole prophylaxis. 
Guidelines also need to clearly deﬁ  ne doses for split-dose 
tablets and if available, syrups or soluble formulations 
(table). Training on co-trimoxazole prophylaxis for 
children and adults needs to be incorporated into the 
HIV/AIDS-related training curriculum taught to 
clinicians, nurses, and other care providers. The co-
Panel 1: Initiation of co-trimoxazole prophylaxis in 
infants and children*
HIV-exposed infants and children†
Co-trimoxazole prophylaxis is universally indicated, 
starting at 4–6 weeks after birth and continued until 
cessation of risk of HIV transmission and exclusion of HIV 
infection
Infants and children with conﬁ  rmed HIV infection‡
Infants aged less than 1 year
Co-trimoxazole prophylaxis is indicated regardless of CD4 
percentage or clinical status§
Children aged 1–4 years
Co-trimoxazole prophylaxis is indicated for (1) WHO clinical 
stages 2, 3, and 4 regardless of CD4 percentage or (2) any 
WHO clinical stage (1–4) and CD4-cell count less than 25%
Children aged 5 years or more
Co-trimoxazole prophylaxis is indicated for (1) WHO clinical 
stage 3 or 4 regardless of CD4 level or (2) any WHO clinical 
stage and CD4-cell count less than 350 cells/μL¶
Universal option
Prophylaxis for all infants and children born to mothers 
conﬁ  rmed or suspected of living with HIV. This strategy 
may only be considered in settings with a high prevalence 
of HIV, high infant mortality caused by infectious diseases, 
or limited health infrastructure
*Adapted from WHO guidelines.
23 †Deﬁ  ned as a child born to an HIV-positive mother 
or a child breastfeeding from an HIV-positive mother until HIV exposure stops (6 
weeks after complete cessation of breastfeeding), and infection can be excluded. ‡In 
children younger than 18 months, HIV infection can only be conﬁ  rmed by virological 
testing. For children older than 18 months, HIV infection can be conﬁ  rmed by HIV 
antibody testing. §Once a child is started on co-trimoxazole, treatment should con-
tinue until 5 years of age regardless of clinical symptoms or CD4 percentage. 
Speciﬁ  cally, infants who begin co-trimoxazole prophylaxis before the age of 1 year 
and who subsequently are asymptomatic and/or have CD4-cell count ≥25% should 
remain on co-trimoxazole prophylaxis until they reach 5 years of age. ¶Countries 
may choose to adapt a CD4 threshold of 200 cells/μL where Pneumocystis jirovecii and 
toxoplasmosis are the major targets for co-trimoxazole prophylaxis and where bac-
terial infections and malaria are not prevalent.
Panel 2: Recommendations for discontinuing 
co-trimoxazole in infants and children*
HIV-exposed children
Discontinue co-trimoxazole prophylaxis after HIV infection is 
excluded†
Infants and children with HIV‡
Until age 5 years
Maintain co-trimoxazole prophylaxis irrespective of clinical 
and immune response
Over age 5 years
Reassess and consider discontinuation on the following 
grounds:
CD4 testing not available:
• Do  not  discontinue  co-trimoxazole  prophylaxis, 
particularly in settings where bacterial infections and 
malaria are common HIV-related events
•  Consider discontinuing co-trimoxazole prophylaxis in 
children with evidence of good clinical response to ART 
(absence of clinical symptoms for at least 1 year of 
therapy), good adherence, and secure access to ART
CD4 testing available: 
•  In countries where co-trimoxazole prophylaxis is 
recommended only for preventing Pneumocystis jirovecii 
and toxoplasmosis, it can be discontinued with evidence 
of immune recovery on ART (CD4-cell count ≥200cells/μL 
after at least 6 months of ART)
•  In countries with a high prevalence of bacterial infections 
and malaria, discontinue co-trimoxazole prophylaxis in 
children with evidence of immune recovery related to ART 
(CD4-cell count ≥350 cells/μL after at least 6 months of 
ART)
ART=antiretroviral therapy. *Adapted from WHO guidelines.
23 †In children younger 
than 18 months, HIV infection can only be conﬁ  rmed by virological testing. For those 
older than 18 months, HIV infection can be conﬁ  rmed by HIV antibody testing. 
‡Applies only to discontinuation related to immune restoration on ART. http://infection.thelancet.com   Vol 7   October 2007  689
Review
trimoxazole policy should also be incorporated into 
guidelines and ongoing training involving integrated 
management of childhood illnesses (IMCI), PMTCT, 
tuberculosis, and HIV/AIDS care. 
Limited identiﬁ  cation and recruitment of HIV-exposed 
and HIV-infected children for co-trimoxazole
Opportunities for early identiﬁ   cation of HIV-exposed 
children are limited for three main reasons. First, 
coverage of PMTCT programmes in countries with a 
high prevalence of HIV remains low,
29 meaning that 
most HIV-exposed infants are not being identiﬁ  ed or are 
being lost from the health system.
34 Second, countries 
with a high burden of HIV have not maximised the 
opportunity of child-health programmes such as the 
Expanded Program of Immunisation (EPI) to identify 
HIV-exposed children. For example, in Swaziland where 
the antenatal HIV prevalence rate is particularly high 
(estimated to be 42%), about four out of every ten children 
attending EPI and child clinics could be considered HIV-
exposed. Of these children, one to two are likely to be 
HIV-infected and could beneﬁ  t from early HIV testing, 
co-trimoxazole, and ART. Finally, the high possibility of 
obtaining false-positive results from antibody-based rapid 
HIV tests in children under 18 months of age born to 
HIV-positive mothers in resource-limited settings makes 
it diﬃ     cult to determine infection in HIV-exposed 
children. This problem is a major policy bottleneck for 
early administration of co-trimoxazole prophylaxis and 
ART,
24 since health systems in some countries are 
unwilling to provide co-trimoxazole to children unless 
HIV infection is conﬁ  rmed. Furthermore, care providers 
at diﬀ  erent levels of the health system have not been 
adequately trained to be able to maintain a high index of 
suspicion for recognition of signs and symptoms 
suggestive of HIV infection in children. Opportunities 
for active recruitment have also been grossly under-used 
or missed in voluntary counselling and HIV-testing sites, 
clinics for under-5-year-olds, the general out-patient 
department, and sites visited by people at high risk of 
HIV infection, such as tuberculosis clinics, paediatric 
wards, and paediatric nutritional rehabilitation units. 
Actions required
Eﬀ  orts should be made to rapidly accelerate the expansion 
of PMTCT services as an essential component of routine 
maternal and child-health services at all levels of the health 
system. This action would allow early detection of HIV-
positive mothers and children eligible for both ART and 
co-trimoxazole prophylaxis. Advocacy for the development 
of speciﬁ  c, easy-to-use, and aﬀ  ordable HIV diagnostics for 
identifying HIV infection in children under 18 months of 
age is urgently required. At the moment, the only way of 
conﬁ  rming HIV infection in this age-group is through 
virological antigen testing (eg, with PCR), which is only 
available in a few countries or at limited sites. In practice, 
this poses a practical dilemma to policymakers and 
clinicians in most countries, since it means one of two 
choices: (1) blanket administration of co-trimoxazole to all 
children under 18 months of age born to HIV-positive 
mothers in line with WHO/UNICEF recommendations, 
or (2) waiting until the HIV status is conﬁ  rmed  at 
18 months, by which time infection-related mortality, 
including mortality caused by P jirovecii pneumonia, 
would have taken its toll on a large proportion of HIV-
infected children.
23  
Where PCR is available, eﬀ  orts should be made to test 
the infant 6 weeks after cessation of breastfeeding to 
eﬀ  ectively target continuation of co-trimoxazole to only 
infants that have conﬁ  rmed infection. In settings where 
PCR is not yet available, in light of high mortality, infants 
and children under the age of 18 months should be 
promptly oﬀ  ered co-trimoxazole and considered for ART 
on a presumptive basis until a deﬁ  nitive HIV diagnosis is 
made after 18 months.
4,35 For countries where logistic and 
other operational constraints challenge the feasibility of 
oﬀ  ering co-trimoxazole to all HIV-exposed children under 
18 months of age, a compromise strategy would be to oﬀ  er 
co-trimoxazole to all children born to HIV-positive mothers 
from 4–6 weeks until 6 months of age, when the risk of 
P jirovecii pneumonia-related mortality is highest.
23 
Clinicians, nurses, and care providers need training to 
recognise possible HIV-related clinical features in infants 
and young children at all sites where there is contact with 
children. In settings where HIV prevalence is high, such 
Recommended daily dose Suspension
(5 mL syrup; 
200 mg/40 mg)
Paediatric tablet
(100 mg/20 mg)
Single strength adult tablet
(400 mg/80 mg)
Double strength 
adult tablet
(800 mg/160 mg)
Less than 6 months 100 mg sulfamethoxazole/
20mg trimethoprim
2·5 mL One tablet A quarter of a tablet, possibly mixed 
with feeding
NA
6 months to 5 years 200 mg sulfamethoxazole/
40 mg trimethoprim
5 mL Two tablets Half a tablet NA
6–14 years  400 mg sulfamethoxazole/
80 mg trimethoprim
10 mL Four tablets One tablet Half a tablet
15 years or more 800 mg sulfamethoxazole/
160 mg trimethoprim
NA NA Two tablets One tablet
NA= applicable. Doses of formulations shown as sulfamethoxazole/trimethoprim.
Table: Co-trimoxazole formulations and dosage for infants and children with HIV infection or exposed to HIV infection690   http://infection.thelancet.com   Vol 7   October 2007
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as tuberculosis clinics and nutritional rehabilitation 
units, health-care workers should also be encouraged 
to routinely oﬀ  er HIV testing.
28 
Approach to HIV testing in pregnant women, 
symptomatic children, and at high-risk sites
HIV testing in pregnant women, symptomatic children, 
and at high-risk sites (ie, health-care facilities visited by 
people at high risk of HIV infection) have until now 
involved an “opt-in” approach that is client-initiated. 
HIV testing and case-ﬁ  nding was therefore passive and 
did not facilitate knowledge of HIV status.
Actions required
HIV testing in these three speciﬁ  c groups needs to 
move towards an “opt-out” or active approach that is 
health-provider initiated.
36 For pregnant women 
attending PMTCT programmes, HIV testing should be 
oﬀ   ered routinely as part of a standard screening 
package (provider-initiated testing and counselling 
[PITC]).  Understandably, the barriers preventing the 
scale-up of HIV testing in pregnant women in diﬀ  erent 
countries might be highly contextual and scalability, 
acceptance, and feasibility might vary. However, 
experience from Botswana
37,38 and Zimbabwe
39 shows 
that introduction of a PITC approach in antenatal 
services with rapid, same-day results greatly increases 
uptake of HIV testing and the percentage of women 
receiving PMTCT interventions. These ﬁ  ndings 
highlight the potential public-health impact of 
introducing PITC within programmes that attempt to 
increase the number of people with access to HIV 
prevention and treatment services. Thus, despite the 
myriad of potential logistic and social barriers to HIV 
testing that might exist in diﬀ  erent  contexts, 
introducing the PITC approach would be the ﬁ  rst 
important step for increasing acceptance and knowledge 
of HIV status as well as uptake of PMTCT interventions. 
For infants and children who present with symptoms 
or signs that could be attributable to HIV infection, 
HIV testing should be routinely oﬀ  ered in an opt-out 
manner as part of the diagnostic work-up for patients 
and a basic standard of care (diagnostic HIV testing 
and counselling, DTC). High-risk sites such as 
tuberculosis clinics, paediatric wards, and nutritional 
rehabilitation units should be considered a priority for 
DTC because this will increase the chance of HIV case-
ﬁ  nding in children. For example, a study in Botswana 
showed that 60% or more children admitted to 
paediatric wards in major hospitals were HIV-positive.
40 
In such a country, moving to an active DTC strategy 
could increase the number of children identiﬁ  ed as 
HIV-postitive and improve their eventual outcomes in 
terms of morbidity and mortality.
40 HIV-testing 
guidelines need to include explicit guidance on PITC 
and DTC, and counsellors and care providers must be 
adequately trained.
35 
Prescriptions of co-trimoxazole prophylaxis are 
restricted to isolated HIV/AIDS clinics
Although identiﬁ  cation of HIV-exposed infants and HIV-
infected children might occur at diﬀ  erent sites in the 
health system, patients are often obliged to present 
themselves to specialised HIV/AIDS clinics, often located 
in hospital settings, if they are to receive a prescription of 
co-trimoxazole prophylaxis. This means additional 
waiting times in queues, the need for separate visits, or 
long distance travel to hospitals for monthly prescription 
reﬁ   lls. The latter is an important barrier for those 
committed to continuing prophylaxis; one of the main 
reasons for stopping prophylaxis is the high cost of 
transport to distant health facilities.
41
It is much more convenient to provide a 3-month rather 
than 1-month supply of drugs when distance and 
transport costs are issues and this is likely to improve 
adherence. 
Actions required
An integrated one-stop service that provides co-
trimoxazole prescriptions at all sites where there is 
contact with children would foster a patient-friendly 
approach. In particular, children who are born to HIV-
infected mothers or children identiﬁ  ed as being HIV-
positive through voluntary counselling and HIV-testing 
clinics, clinics for under 5-year-olds, the general out-
patient department, tuberculosis clinics, or nutritional 
rehabilitation units should be given a prescription of co-
trimoxazole (on site) for their mothers to take to the 
pharmacy for collection of the drugs provided there are 
no contraindications.   
To improve access for continued co-trimoxazole 
prophylaxis, drug reﬁ  lls should be made readily available 
at decentralised sites including health centres and home-
based care programmes. All health workers or members 
of multidisciplinary care teams should be able to 
prescribe co-trimoxazole.    
Inadequate information, education, and 
communication advocating co-trimoxazole
Because of policymakers’ concerns about eﬀ  ectiveness 
and development of drug resistance following widespread 
use of co-trimoxazole at country level, little or no 
emphasis had been placed on developing speciﬁ  c 
information, education, and communication messages 
advocating co-trimoxazole within health services or the 
community. Individuals that use health services might 
therefore be insuﬃ   ciently aware of the beneﬁ  ts of co-
trimoxazole prophylaxis. 
Actions required
There is an urgent need to develop speciﬁ  c messages to 
increase awareness and the demand for co-trimoxazole 
both among health workers and in the community. Such 
messages should be simple and clear—for example, 
“taking your daily doses of co-trimoxazole could provide  http://infection.thelancet.com   Vol 7   October 2007  691
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you with protection from a number of common HIV-
related illnesses including malaria and diarrhoea, 
considerably reducing your risk of death from HIV/AIDS, 
therefore providing you with beneﬁ   ts before starting 
ART and also while on ART”. 
Motivational talks advocating the use of co-trimoxazole 
in the community and within diﬀ  erent health services 
should be routinely done by a joint team of health workers 
and people living with HIV/AIDS. 
Problems with co-trimoxazole drug supply and 
monitoring
Most national programmes do not have systems for 
accurately estimating programme needs or for monitoring 
consumption related to prophylaxis. Co-trimoxazole drug 
supplies provided to health facilities are used rather 
blindly for both treatment and prophylaxis. Co-
trimoxazole stock shortage is therefore a common 
operational problem that directly hampers initiating and 
continuing prophylaxis. For example, in a recent national 
survey in Malawi at 94 public-health facilities providing 
ART, 55% of facilities were out of stock of co-trimoxazole 
at the time of the supervisory visit (HIV Unit, Ministry 
of Health, Malawi, unpublished data).
Actions required
An initial estimate of national requirement would need 
to be calculated to decide how much co-trimoxazole is 
required as a “kick-start” for central medical stores. The 
pharmacy in each health facility should centralise 
supplies of co-trimoxazole for patients and should keep 
a “vital register” of co-trimoxazole prophylaxis. Patients 
should be given a unique co-trimoxazole registration 
number and this number plus name, age, and sex 
should be listed on the register. The unique registration 
number will also be written on the patient card or health 
passport if this exists. Every time a patient is given co-
trimoxazole, the date should be entered into the register. 
Therefore, the number of patients (adults and children) 
who start co-trimoxazole and the number who continue 
co-trimoxazole can be monitored by regular checks of 
the vital register. The use of such registers merits pilot 
testing and would certainly help with logistics of 
procurement and distribution. 
Co-trimoxazole should be supplied through existing 
drug distribution systems and should be provided free 
of charge. Districts will need to ensure that a “budget 
line” is created for co-trimoxazole prophylaxis and that 
there is an uninterrupted supply of the drug for both 
treatment and prophylaxis. There will be a need to 
designate a responsible authority at national level who 
monitors the scale-up of co-trimoxazole prophylaxis. 
Lack of implementation plans and targets for children 
Few countries have so far drawn up phased 
implementation plans and a system for monitoring and 
reporting of progress.
Actions required
A phased plan for scale-up and integration of co-
trimoxazole prophylaxis in children within existing 
child-care and HIV services, including speciﬁ  c 
population targets and indicators, should be developed. 
A minimum set of indicators could include: the existence 
of an eﬀ   ective national coordination mechanism; 
existence of a national policy on co-trimoxazole 
prophylaxis; a co-trimoxazole scale-up plan, with 
budgetary allocation; the proportion of HIV-exposed 
infants in PMTCT programmes who receive co-
trimoxazole prophylaxis at 6–8 weeks; and the proportion 
of HIV-infected children within existing health services 
(including paediatric HIV care, IMCI, nutritional 
rehabilitation units, and home-based care) who access 
co-trimoxazole.
Although co-trimoxazole implementation could provide 
a useful and crucial entry point on which to build other 
interventions, by no means should it lead to the 
Panel 3: Programmatic issues and logistic/operational considerations linked to 
implementing co-trimoxazole prophylaxis in children
Policy and programme implementation
•  National guidelines on clinical care, ART, and PMTCT to include co-trimoxazole 
prophylaxis as a part of the basic care package
•  Ensuring availability of appropriate doses and drug formulations for children
•  Assessing legal and policy options to allow co-trimoxazole access at all sites that have 
contact with HIV-exposed and HIV-infected children
•  Provision of co-trimoxazole free of charge to children
•  Inclusion of co-trimoxazole for preventive HIV treatment in the essential drug kit
HIV testing
•  Training of health providers in antenatal care, child-health programmes, tuberculosis 
clinics, paediatric wards, and nutritional rehabilitation units on the provider-initiated 
HIV testing and counselling (opt-out) approach
•  Provision of infrastructure space and rapid test kits for HIV testing and counselling
•  Increasing access to virological testing to aid early identiﬁ  cation of HIV-infected 
children
Patient information
•  Adapted information, education, and communication tools targeting health providers 
and patients to promote co-trimoxazole prophylaxis in children
Drug stocks and supplies
 •  Introducing co-trimoxazole vital registers to ease calculation of consumption and 
forecasts of drug needs
•  Existing drug distribution systems to include integrated management of procurement 
and supply
•  Ensuring uninterrupted drug supply for treatment and prophylaxis
• Speciﬁ  c budget allocation for co-trimoxazole
Monitoring and evaluation
•  Regular reporting of uptake of co-trimoxazole within speciﬁ  c programmes and 
evaluation against set targets
•  National surveillance of antimicrobial resistance of pneumonia, dysentery, and malaria 
in children
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propagation of a vertical co-trimoxazole programme. 
What is needed is to link co-trimoxazole as an integral 
part of a standard package of care within PMTCT, ART, 
and other child-health programmes, including 
distribution of insecticide-treated bednets for malaria 
prevention and safe-water vessels. 
Programmatic issues and logistic/operational 
considerations
The main programmatic issues and actions required 
regarding the logistic and operational aspects linked to 
oﬀ   ering co-trimoxazole prophylaxis in children are 
highlighted in panel 3. 
Funding gaps in high HIV-prevalence settings
Although co-trimoxazole is cheap, large-scale 
implementation of co-trimoxazole prophylaxis in settings 
with a high prevalence of HIV will need substantial 
resources and logistics. With a conservative global 
estimate of 2·8 million children requiring co-trimoxazole 
in 2005 (2·3 million HIV-infected children and 530  000 
new HIV infections),
1 this would amount to 
US$8·5–23 million per year on drug costs only, using an 
estimated annual cost of $3–8 per child.   
Actions required
Development partners and donor countries should 
support widespread implementation of co-trimoxazole 
prophylaxis and ensure that co-trimoxazole is included as 
a speciﬁ   c component in funding proposals. Co-
trimoxazole for HIV-exposed and HIV-infected children 
should be considered a priority intervention that is 
included in scale-up of paediatric HIV care and 
treatment.
Conclusions
There are considerable clinical and operational beneﬁ  ts 
of oﬀ   ering co-trimoxazole prophylaxis to children in 
countries with a high prevalence of HIV. Serious eﬀ  orts 
need to be made to scale-up this widely available and 
easy-to-use medication.
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